We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




First-of-Its-Kind Technology Repairs and Regenerates Heart Muscle Cells

By HospiMedica International staff writers
Posted on 17 Jun 2022

A first-of-its-kind technology not only repairs heart muscle cells in mice but also regenerates them following a heart attack, or myocardial infarction as it is medically known. More...

The groundbreaking finding has the potential to become a powerful clinical strategy for treating heart disease in humans.

The new technology developed by a team of researchers at the University of Houston (Houston, TX, USA) uses synthetic messenger ribonucleic acid (mRNA) to deliver mutated transcription factors - proteins that control the conversion of DNA into RNA - to mouse hearts. The researchers demonstrated that two mutated transcription factors, Stemin and YAP5SA, work in tandem to increase the replication of cardiomyocytes, or heart muscle cells, isolated from mouse hearts. These experiments were conducted in vitro on tissue culture dishes.

Stemin turns on stem cell-like properties from cardiomyocytes and played a crucial role in the experiments, with the transcription factor being a “game changer.” Meanwhile, YAP5SA works by promoting organ growth that causes the myocytes to replicate even more. In a separate finding, the team has reported that Stemin and YAP5SA repaired damaged mouse hearts in vivo. Notably, myocyte nuclei replicated at least 15-fold in 24 hours following heart injections that delivered those transcription factors.

An added benefit of using synthetic mRNA, according to the researchers, is that it disappears in a few days as opposed to viral delivery. Gene therapies delivered to cells by viral vectors raise several biosafety concerns because they cannot be easily stopped. mRNA-based delivery, on the other hand, turns over quickly and disappears. The findings are especially important because less than 1% of adult cardiac muscle cells can regenerate. When there is a heart attack and heart muscle cells die, the contracting ability of the heart can be lost.

“No one has been able to do this to this extent and we think it could become a possible treatment for humans,” said Robert Schwartz at the UH College of Natural Sciences and Mathematics who led the study. “When both transcription factors were injected into infarcted adult mouse hearts, the results were stunning. The lab found cardiac myocytes multiplied quickly within a day, while hearts over the next month were repaired to near normal cardiac pumping function with little scarring.”

“What we are trying to do is dedifferentiate the cardiomyocyte into a more stem cell-like state so that they can regenerate and proliferate,” said recent Ph.D graduate Siyu Xiao. “This is a huge study in heart regeneration, especially given the smart strategy of using mRNA to deliver Stemin and YAP5SA.”

Related Links:
University of Houston 


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.